Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...

The Foundation for Sarcoidosis Research (FSR) is proud to announce the three recipients of the 2025 FSR Early Career Fellowship Grant: William Lippitt, PhD, (University of Colorado Anschutz Medical ...